卵巢癌初次减瘤术后化疗延迟的关联研究
基于美国国家癌症数据库1998-2011年符合NCCN指南治疗的卵巢癌队列,58.1%(26,149/45,001)女性发生化疗延迟(初次减瘤术后>28天开始多药化疗)。化疗延迟>35天与死亡风险增加7%(95%CI 2-13%,P=0.01)相关,术后21-35天区间内生存无显著差异。
要点
- 化疗延迟定义为初次减瘤术后>28天开始多药化疗,58.1%患者发生延迟。
- 延迟>35天与死亡风险增加7%(95%CI 2-13%,P=0.01)相关。
- 术后25-29天死亡相对风险最低,21-35天区间内无显著差异。
核心结论
- 在初次减瘤术后21至35天之间一致地开始化疗可能获得生存获益。
- 化疗延迟风险较高的女性可被针对进行密切随访。
研究设计与样本
- 观察性回顾性队列分析,使用1998-2011年美国国家癌症数据库,纳入接受NCCN指南一致治疗的卵巢癌女性。
- 化疗延迟定义为初次减瘤术后>28天开始多药化疗。
- 采用多因素logistic回归检验患者和疾病特征与化疗延迟的关联。
- 对2003至2006年诊断的女性进行生存分析,近似21天周期静脉铂-紫杉烷化疗队列。
- 采用Kaplan-Meier分析和Cox比例风险回归估计总生存,并使用匹配队列进行敏感性分析。
主要发现
- 58.1%(26,149/45,001)的女性经历化疗延迟。
- 种族、保险状态、癌症中心类型和社区中位收入与化疗延迟显著相关(P<0.001)。
- 年龄较大或病情较重、子宫内膜样或黏液性组织学、较低分期或分级疾病、无保险或低收入女性的化疗延迟比值比更高(P<0.05)。
- 化疗延迟>35天与死亡风险增加7%(95%CI 2-13%,P=0.01)相关。
- 术后25至29天死亡相对风险最低,但在21至35天较长两周区间内无显著差异。
临床怎么用
- 作者认为,在初次减瘤术后21至35天之间一致地开始化疗可能获得生存获益。
- 作者认为,化疗延迟风险较高的女性可被针对进行密切随访。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the association of chemotherapy delay with overall survival (OS) and investigate predictors of delay among a population-representative American ovarian cancer cohort. METHODS: An observational retrospective cohort analysis of women with ovarian cancer who received National Comprehensive Cancer Network guideline-consistent care was performed with the 1998-2011 National Cancer Data Base. Chemotherapy delay was defined as initiation of multiagent chemotherapy >28days from primary debulking surgery. Associations of patient and disease characteristics with chemotherapy delay were tested with multivariate logistic regression. Survival analyses for women diagnosed from 2003 to 2006 approximated a 21-daycycle intravenous platinum-taxane chemotherapy cohort. Overall survival was estimated by Kaplan-Meier analyses and Cox proportional-hazards regressions, with sensitivity analyses using matched cohorts. RESULTS: 58.1% (26,149/45,001) of women experienced chemotherapy delay. Race, insurance status, cancer center type, and community median income were significantly associated with chemotherapy delay (P<0.001). Odds for chemotherapy delay were higher for older or sicker women, women with endometrioid or mucinous histology, lower stage or grade disease, and uninsured or low-income women (P<0.05). Chemotherapy delay >35days from surgery was associated with a 7% (95% confidence interval, 2-13%) increased hazard of death (P=0.01). Relative hazard of death was lowest between 25 and 29days after surgery but was not significantly different within the longer two-week interval from 21 to 35days. CONCLUSION: A survival benefit may be achieved by consistently starting chemotherapy between 21 and 35days from primary debulking surgery. Women at higher risk for chemotherapy delay may be targeted for close follow-up.
引用
- Seagle BL, Butler SK, Strohl AE, et al. Chemotherapy delay after primary debulking surgery for ovarian cancer. Gynecol Oncol. 2016. PMID: 27908531. doi:10.1016/j.ygyno.2016.11.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。